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Background: Myxomatous degeneration of the mitral valve is a common pathological finding in mitral valve
surgery and the most common reason for severe mitral valve regurgitation. Considering the importance of right
ventricular remodeling and global function after mitral valve surgery we tried to elucidate a possible association of
myxomatous mitral valve and impairment of right atrial and ventricular function, which might have an impact on
global ventricular performance after mitral valve surgery.
Methods: Right atrial tissue was harvested from 47 patients undergoing mitral valve surgery. We took the
trabeculae from the right auricle, which was resected at the right auricle for implementation of extracorporal
circulation. The tissue was skinned and prepared in a 24 h-lasting procedure to create small fibers for hinging them
in the “muscle machine”, an experimental set-up, created for pCa-force measurements.
Results: Patients without myxomatous mitral valve developed significantly more force (4.0 mN ± 0.8 mN) at the
highest step of calcium concentration compared to 2.7 mN ± 0.4 mN in group of patients with myxomatous valve
degeneration (p 0.03). Calcium sensitivity in the myxomatous valve group was at pCa 6.0 and in the non-myxomatous
group at pCa 5. Furthermore we observed a significant difference in ejection fraction (EF) among the groups: 49% in
the non-myxomatous group versus 57% in the myxomatous group (p 0.03). In the non-myxomatous group 5 patients
had diastolic dysfunction grade I-II (22,7%), in group I 10 patients (40%). This was also significant (p 0.04).
Conclusions: Patients with myxomatous mitral valve degeneration seem to have reduced force capacities. Calcium
sensitivity is higher compared to the non-myxomatous group, which might be a compensatory mechanism to cover the
physiological demand. Furthermore we suggest a higher incidence of diastolic dysfunction in patients with myxomatous
mitral valve degeneration, which might have an impact on ventricular remodeling after mitral valve surgery.
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Myxomatous degeneration of the mitral valve is a common
pathological finding in mitral valve surgery (Figure 1).
The histological findings of myxomatous mitral valve
degeneration (MMVD) include that mitral valve leaflets are
more extensible and less stiff circumferentially and radially
compared to normal mitral valves [1,2]. Furthermore
chordae are longer and leaflets are enlarged, thus failing* Correspondence: constanze.bening@googlemail.com
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unless otherwise stated.at significantly lower tensile stress than normal chordae
[2]. Additionally enlargement of the mitral annulus
accompanies myxomatous valve disease. The tri-layered
structure of the valve as well as the organization of the
matrix structure is destroyed by accumulation of mechan-
ically inadequate glycosaminoglycans which are increased
in this tissue [3]. Further collagen fibrils change their
organization structure and loose mechanical stability and
flexibility [4]. This finding is not uncommon and also
often found in a localized form [5]. This histological char-
acteristic can also be associated with degenerative valvular
diseases like M. Barlow, Marfan’s syndrome or fibroelasticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Myxomatous Mitral Valve Leaflet.
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but can also be found in the elderly [5] which might allow
the assumption of MMVD to be a symptom of ageing of
the valve.
But this finding is not new: The first description of
myxomatous mitral valves can already be found in 1910
(Dewitzky, Felsenreich and von Weisner 1915). It was
found to be more common in the posterior cusp, but it
was thought to have no hemodynamic significance,
although it was assumed, that incidence increases with
age [5]. The assumption of being a sign of ageing comes
from examinations with canines: a wide range of examina-
tions were performed in dogs, because the myxomatous
mitral valve degeneration (MMVD) is the most common
cardiac disease in dogs and there are strong evidences
for a close dependency of age and this disease [6]. Some
analogies absolutely exist between humans and dogs [7].
Nevertheless some inconsistencies exist: the prevalence
of MMVD in humans is estimated at 2-3% and is described
to be equally distributed among men and women [8],
although mitral valve prolapse affects more women
than men [9]. There are some evidences in humans for
the association of ageing and accompanying pathological
conditions in patients with myxomatous mitral valves but
the etiology and associated lesions are not clear, but issue
of various assumptions [5].
Read defined the myxomatous mitral valve as the
“floppy valve syndrome” and thought it to be a special
entity of the Marfan’s syndrome [10,11].
So clear definitions as well as possible genetic associations
remain uncertain. However it seems obvious that patients
with a myxomatous mitral valve do not show any clinical
signs of impairment of cardiac function and thereforeclinical relevance seems to be of academically interest, but
the affection of the mechanical properties (i.e. ruptured
chordae, prolapse, deformed cusps) due to myxomatous
degeneration [1,2] especially in older patients can be rapidly
fatal and might influence the outcome and survival.
The issue of taking right atrial tissue, follows some inten-
tions: There are many studies about the left ventricular and
left atrial function in chronic mitral regurgitation or
patients undergoing mitral valve surgery [12,13], which
show a significant impairment of LA filling, LA contraction
and ejection fraction as well a latent LV dysfunction in
patients with mitral regurgitation. But investigations about
right ventricular and atrial function after cardiac surgery
and especially mitral valve surgery are still rare. Although
impaired right ventricular function after mitral valve surgery
is associated with poor survival rate [14] and impairment of
right ventricular function is frequent (30%) and a strong
predictor of postoperative cardiovascular survival [13].
As a second clinical interest could be the assumption
that the condition of possible association of myxomatous
mitral valve and impairment of right atrial and/or ventricu-
lar function might have an impact on ventricular perform-
ance and remodeling after mitral valve surgery and might
influence the decision of surgical repair or replacement of
the valve [15].
Therefore we underwent a study to examine a potential
impairment of contractile function in patients with myxoma-
tous mitral valve undergoing valve replacement or repair.
Methods
Patients
We observed 47 patients undergoing mitral valve repair
(MVr) or mitral valve replacement (MVR) and divided
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(see Table 1). We harvested the tissue intraoperatively and
collected the pathological findings afterwards. 25 patients
had a myxomatous degeneration (53%). In the myxomatous
mitral valve group (group I) the mean age was 60 ± 16 years
and consisted of 13 males and 12 females. 16 patients
showed as leading feature mitral valve regurgitation (64%),
9 patients a mitral valve stenosis (36%) also as leading
feature (Not isolated valve stenosis). The mean EF in this
group was 57%. 12 patients underwent a mitral valve repair
(48%) and 13 replacement of the valve (52%).
The group of patients without myxomatous mitral valve
(group II) consisted of 22 patients with 8 males (36%) and
14 females (63%). The mean age was 67 ± 13 years. 20
patients showed as leading echocardiographic finding
a mitral regurgitation (90%) and 2 patients a valve
stenosis (10%). The mean EF was 49%. 16 patients under-
went a mitral valve repair (72.7%) and 8 patients had
a replacement (36.3%).
We did not see isolated mitral valve stenosis, but a
combination of regurgitation and stenosis. So a rheumatic
disease can be nearly excluded.
Classification
We classified the patients in two groups with the histo-
pathological finding of myxomatous degeneration of
the tissue (Group I: Myxomatous mitral valve and group
II: non myxomatous mitral valve). The tissue for the
experimental set-up was taken from the right auricle
before implementation of the extracorporal circulation.
Ethic’s approval is available (According to § 14 AVB,Table 1 Patient’s clinical characteristics
Myxomatous MV Non-Myxomatous MV p
Age 60 ± 16 years 67 ± 13 years n.s.
Gender 13 Males (52%) 8 Males (36%) n.s.
12 Females (48%) 14 Females (63%)
Leading Valve
Pathology Regurgitation (64%) Regurgitation (90%) n.s.
Stenosis (36%) Stenosis (10%)
Surgical Procedure
Repair 48% 72.7% 0.02
Replacement 52% 36.3% n.s.
Ejection Fraction: 57% 49% 0.03
Atrial Dilatation 36% 68% 0.01
Ventricular Dilat. 12% 13% n.s.
Annulus Dilat. 4% 9% n.s.
Atrial Fibrillation 24% 38% n.s.
Valve Prolapse 36% 27% 0.02
Diastolic
Dysfunction 40% 22.7% 0.04Absatz 3: Patients, who will be admitted to the University
Hospital will be informed and asked, if they agree to use
tissue, that will be withdrawn within the operation,
for research work. This tissue can be used without making
further applications at the ethical review committee;
http://www.laek-rlp.de).
Pathological examination
The tissue was examined in the department of pathology.
The tissue was microscopically examined by performing a
haematoxylin-eosin staining.
Experimental set-up
The tissue was transported in an oxygenated cardioplegic
solution containing BDM (Butanedione-Monoxim, 30 mM)
to the laboratory and prepared in a special way: skinned
fibers were prepared while being incubated in a special
solution containing 50% glycerol (Contents [mM]:
Imidazole 20; Sodium azide 10; EGTA 4; Dithioerythriol 2;
Magnesium chloride 5; ATP 5; ph 7) and subsequently
stored in the same solution, containing 1% Triton-X-100
in addition, for 24 hours at 4°C. For our experimental
approach we used skinned muscle stripes with a size
of 2–2,5 mm × 0,3 mm, which were finally mounted
on a force transducer. We took 3 fibers from each
patient to perform the examination.
The approach with skinned fiber is well established in
our laboratory. First described from Weber and Portzehl
[16] it is a safe and reproducible method to remove
cell-membrane dependent processes and to create an
artificial experimental environment for examining the
contractile apparatus. The fibers are first exposed to a
so-called relaxation solution (Contents [mM]: Imidazole 20,
Phosphocreatine 10; Sodium azide 10; EGTA 10; Magne-
sium chloride 25; Dithioerythriol 2; ATP 20 and 400 U/ml
creatine kinase) and prestrechted to 20 mg. After achieving
the force baseline, the experimental cycle starts. The
calcium concentration starts at pCa 6.5 and increases
stepwise to pCa 4.0 in the contraction solution, in which
EGTA was substituted by CaEGTA. The desired calcium
concentrations were calculated by a computer program,
following the equation of Fabiato & Fabiato and given as
pCa (−log of free [Ca]2++). The measured pCa-force values
are recorded and collected on the attached computer
(Scientific Instruments, Heidelberg, Germany).
Statistical analysis
We performed the Wilcoxon rang sum test as a non-
parametric test for non-normal distributions. Statistical
significance was defined at a level of 5%.
Results
Patients without myxomatous mitral valve develop 4.0
mN± 0.8 mN at the highest step of calcium concentration
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tous valve degeneration (Figure 2). This was significant less
force in group I (p 0.03). When we compare the force
values at the other 5 steps of calcium concentration we see
significant differences in the higher calcium concentrations
whereas the lower concentration do not show any
significant difference: pCa 4.5 1.9 ± 0.8 mN (group I) ver-
sus 2.8 mN± 1.2 mN (group II), p: 0.04 and at pCa 5.0: 1.8
mN± 0.8 mN (group I) versus 2.3 mN ± 0.6 mN (group
II), p: 0.05. At pCa step 5.5 group I achieves 1.7 mN± 0.6
versus 1.8 ± 0.3 mN, at pCa 6.0 1.6 mN ± 0.4 versus 1.7
mN± 0.3 and at the lowest concentration 0.4 mN± 0.05
versus 1.05 mN ±0.2 mN. These force values were
not significant different. But all force values of the
non-myxomatous patients are higher compared to the
myxomatous patients. The largest increase in force can be
seen between pCa 4.5 and 4.0. According to that observa-
tion the calcium sensitivity of the myxomatous group is
higher than in the non-myxomatous group. Calcium sensi-
tivity was in group I at pCa 6.0 and in group II at pCa 5.
Comparing the clinical features we observed in these
two groups, we find some noticeable results:
We observe a significant difference in ejection fraction
(EF) among the groups: 49% in the non-myxomatous
group versus 57% in the myxomatous group (p 0.03).
Furthermore we observed significant higher incidence of
diastolic dysfunction in the myxomatous group: 40% of
the patients had a diastolic dysfunction (grade I-II). One
patient even showed grade III. In group II 5 patients had
diastolic dysfunction grade I-II (22,7%), this was significant
(p 0.04). Six patients (24%) in group I had furthermore
atrial fibrillation and 9 patients (38%) in group II, but this
was not significant (p 0.4). When we have a look to the
pathology of the patients we found significant more
prolapses in the myxomatous group than in these patients
without myxomatous mitral valve (p 0.02). Atrial dilata-
tion occurs in 9 patients (36%), ventricular dilatation in 3Figure 2 Comparison of force capacities of myxomatous and non-my
(p 0.03) and 4.5 (p 0.04).patients in group I (12%). An annulus dilatation appears
in one patient (4%). In group II atrial dilatation emerges in
15 patients (68%), ventricular dilatation occurs in 3
patients (13%), annulus dilatation in 2 patients (9%). The
appearance of atrial dilatation in the non-myxomatous
group is significant (p 0.01). Comparing the surgical
procedure of valve repair or replacement we observed
a significant higher repair of mitral valve (p 0.02) in
the non-myxomatous group (72%) compared to group I
(48%). More than half of the patients in the myxomatous
group underwent a replacement of the valve.
Discussion
The myxomatous mitral valve degeneration has been
studied for many years. As most common indication for
mitral valve surgery due to severe regurgitation, the
main interest so far was the histological and pathological
investigation on the etiology of valve degeneration.
Accordingly a variety of studies exist examining molecular
pathways and the potential role of different molecules like
the transforming growth factor superfamily or several
enzymes [8,13].
From surgical view we wanted to highlight another
aspect of this valve disease: is the myxomatous degener-
ation a local process, taking place in the valves or has a
combined effect on heart function? The right contractile
property is important because right ventricular remodeling
may play an important role in clinical outcome of patients
undergoing mitral valve surgery [17,18].
Our results show that atrial fibers from patients with
myxomatous mitral valve degeneration achieve significant
less force than those from patients without this patho-
logical feature whereas calcium sensitivity is increased in
the myxomatous mitral valve group. However the clinical
findings of the myxomatous mitral valve group would
assume a higher force curve than we found in this group
because of younger age, less atrial as well as ventricularxomatous mitral valves. Significant differences exist at pCa 4.0
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(67 years) and had a mean EF of 49%. Ninety% showed a
mitral regurgitation associated with atrial dilatation (68%)
and the majority was female (63%). The possible reasons
are multifold.
It might reflect the affection of contractile capacity
due to myxomatous degeneration: Brixius observed the
same results in his studies with skinned fibers in failing
and non-failing hearts of human donors and found
higher calcium sensitivity in failing heart fibers with
reduced force capacity [19]. Wankerl [20] furthermore
examined different cardiac diseases with the skinned
fiber model and found increased calcium sensitivity in
atrial fibers in diseases with elevated right atrial pressure
like in mitral valve regurgitation. And according to our
results Arndt [21] furthermore observed in fibers from
right atria of patients suffering from mitral valve disease
increased calcium sensitivity and lower unloaded shorten-
ing velocity. This supports our assumption of compensating
the reduced force with increased calcium sensitivity and
gives some evidence for further impact on contractile
behavior in MMVD.
Assuming that myxomatous mitral valve is not only a
limited valve leaflet disease, we found some similarities
with the patients examined by Matsumaru [22], who
studied clinical and pathological differences of Carpen-
tier’s differentiation of billowing mitral valve disease
(BML) and fibroelastic deficiency (FED) and found that
BML patients are more middle-aged, have a long term
evolution of valve disease, multiple segments of billow-
ing valve, more redundant tissue with a diffuse myxoma-
tous infiltration, significant more dilated annulus and
therefore require a multiple resection/suture technique.
In opposite to that he found the FED patients to be
older with focal myxomatous changes and restriction of
thickening to the limited prolapsing segment. They
mainly present no dilatation of the annulus and there-
fore need a less complicated surgical procedure. We
share this observation of younger age in patients with a
diffuse myxomatous degeneration and can support his
finding of a preserved three-layer architecture of the
leaflet tissue in the FED group, who are older, have more
focal myxomatous changes and underwent more repair
procedures than the younger patients in our myxoma-
tous mitral valve group. Another evidence of impact of
this pathological feature on surgical procedure gives
Flameng [23]: he assessed echocardiographic studies in-
cluding recurrence-free rate after valve repair in M.
Barlow and reported an influence of etiology of myxoma-
tous degeneration on complexity of plasty techniques [23].
An important observation from surgical view was made
Adawil [24]: he gives some additional impressions to our
assumption of the clinical picture consisting of older
age, more recent symptoms and non myxomatous mitralvalves: he found more calcific valves changes and signs of
degeneration [24] and this is according to our results: we
observed a more frequently valve stenosis component in
this group which might give slight evidence for more
annulus and perivalvular calcification. Another possible
reason for reduced forces in the myxomatous group might
also be the higher rate of diastolic dysfunction: There are
several studies in literature, which assume that perturba-
tions at the cellular level like impaired Ca 2+ − handling,
extracellular matrix modification and myofilament dys-
function might cause diastolic dysfunction [25]. In our ob-
servation the diastolic dysfunction, patients was diagnosed
in group I, can affect the force values, which actually were
reduced. The incidence was higher in the myxomatous
valve group and -as increasingly recognized in the past-
diastolic dysfunction can emerge with a preserved left
ventricular function, imaged as normal ejection fraction.
Recent studies showed that 40-50% of patients even with
“congestive heart failure” had an LVEF > 50% [26].
Another possible influencing factor could be the
gender distribution: The higher number of females in
group II might influence the force values: several
studies about contractility and calcium sensitivity illustrate
greater tension and higher calcium sensitivity [27,28]. A
gender dependent impact on the extent of mitral prolapse
was demonstrated by Avierinos et al. [9], who found that
female patients more often have anterior prolapse and
more leaflet thickening and therefore lower regurgitation
grades and higher ejection fraction. This may reflect the
higher force in the non-myxomatous group with female
majority (63%). So a gender related influence on the force
values cannot be excluded.
Conclusion
This study should highlights that myxomatous mitral
valve is not only a pathological diagnosis but has some
clinical aspects, which might influence the surgical ther-
apy and result. In conclusion we observed an association
of myxomatous mitral valve disease with reduced force
capacity, increased calcium sensitivity and higher inci-
dence of diastolic dysfunction. An early therapy of risc
factors especially in patients with valve regurgitation
(volume overload) could be made as a careful recom-
mendation for clinical practice.
Limitations
As mentioned above the variety of possible influencing
factors on cardiac force development is broad. Of course
the complexity of cardiac contraction cycle cannot be
imaged in a single experimental approach, but it might
give some evidence for an affection of myocardial appar-
atus. We are aware that we examine right atrial tissue
and deduce our experimental observation to the right
ventricle, but different studies [8,29] prove a similar
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and studies exist about calcium sensitivity in atrial and
ventricular skinned cardiac fibers in different cardiac
diseases [20], so conclusions seem justified.
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